dG Medical Group partners with local medical research Institutions to perform innovative research on the regenerative properties of Regenerative Protein Arrays (RPA) and their contents. Together with our researchers, we are laying the foundation for the development of clinical RPA products.
Regenerative Protein Arrays (RPA) are multipotent cells that have the ability to differentiate into different cell types, such as bone cells, cartilage cells, fat cells, and muscle cells. Regenerative Protein Arrays (RPA) possess immunomodulatory properties, meaning, among other things, that they can regulate the immune response.
Regenerative Protein Arrays (RPA) are considered advantageous compared to other sources, such as bone marrow or adipose tissue, due to their non-invasive collection process and their abundant supply. The collection of RPA’s does not involve any harm to the mother or the baby, as they are obtained from the placental environment immediately following the birthing process.
Now available to physicians for clinical use.
The use of Regenerative Protein Array (RPA) represents a new frontier in regenerative health solutions. Regenerative medicine is an emerging field and little is known about this in the public sphere outside of the existing cutting-edge innovative research.
Regenerative Protein Arrays (RPA) play a role in intercellular communication and can carry bioactive molecules, such as proteins, nucleic acids, and lipids. In regenerative medicine. Regenerative Protein Arrays (RPA) are being investigated for their potential to promote tissue regeneration, modulate immune responses, and deliver therapeutic payloads to target cells.
Studies have shown that treatments with Regenerative Protein Array (RPA) show similar or better results when compared to stem cell treatment. Based on this information, it is thought that stem cell treatment facilitates its beneficial effects. By using Regenerative Protein Array (RPA) directly, we can eliminate the injection of stem cells which is known to cause potential issues during treatment.
Regenerative Protein Arrays (RPA) are the functional mechanism of the regenerative process. Due to the fact that dG Medical Group’s Regenerative Protein Arrays (RPA) are a cell-free product, they avoid the common risks associated with live cell biologics.
As with any emerging field of medicine, regulatory bodies and authorities have an important role in ensuring the safety and efficacy of Placenta-Derived Protein-based therapies. The FDA has recently notified the industry that all regenerative medicine products intended for clinical use must go through their regulatory process.
D & G Medical Group Inc.
15500 Roosevelt Blvd.
Clearwater, FL 33760
Contact by Phone:
+1 (855) 320-7559
Contact by email:
info@dgmedicalgroup.com
© 2023 | dG Medical Group, Inc. Designed and Powered by Advanced Creative Group
These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.